• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

    51.51 +1.81 (+3.64%)
    Streaming Delayed Price Updated: 11:24 AM EDT, Apr 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about CRISPR Therapeutics AG - Common Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    35 36 Next >
    News headline image
    This Biotech Has a Pipeline That Could Redefine Its Entire Therapeutic Area ↗
    Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years. 
    Via The Motley Fool
    News headline image
    Is This Biotech Stock Your Best Shot at Building a Millionaire-Making Position? ↗
    With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has attracted a big Investor. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now? ↗
    The gene-editing stock has been in a tailspin of late. 
    Via The Motley Fool
    News headline image
    Vertex Pharmaceuticals (VRTX): The Evolution of a Biotech Powerhouse in 2026
    As of March 20, 2026, Vertex Pharmaceuticals (NASDAQ: VRTX) has officially transcended its long-held identity as "the cystic fibrosis (CF) company." For over a decade, the Boston-based biotech giant... 
    Via Finterra
    Topics Intellectual Property
    News headline image
    Is CRISPR Therapeutics Stock a Buy Now? ↗
    We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates. 
    Via The Motley Fool
    News headline image
    3 Monster Stocks to Hold for the Next 10 Years ↗
    They're names worth holding for far longer, but the coming decade could prove particularly fruitful for these companies. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    This Is Why CRISPR Therapeutics Stock Is Tumbling on Tuesday ↗
    Current shareholders were thrown an unexpected curveball that they actually should have been expecting. 
    Via The Motley Fool
    News headline image
    Why Is CRSP Stock Falling Pre-Market Today? ↗
    The company plans to issue $350 million in convertible senior notes that are scheduled to mature in 2031. 
    Via Stocktwits
    News headline image
    RIVN Stock Gains 4% Pre-Market After TD Cowen Upgrade: Analyst Sees Strong Demand For Upcoming R2 Models ↗
    The firm believes the new lineup could significantly expand Rivian's addressable EV market. 
    Via Stocktwits
    Topics Electric Vehicles
    News headline image
    Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of ↗
    These two biotechs have a lot in common. Their differences are even more pronounced. 
    Via The Motley Fool
    News headline image
    Is CRISPR Therapeutics Stock Too Risky to Buy Right Now? ↗
    CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential. 
    Via The Motley Fool
    News headline image
    Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
    Could these three stocks be Cathie Wood's next big winners? 
    Via The Motley Fool
    Topics ETFs
    News headline image
    Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off? ↗
    The past few years have been challenging for the biotech. 
    Via The Motley Fool
    News headline image
    The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices ↗
    Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗
    These biotech companies have catalysts ahead. 
    Via The Motley Fool
    News headline image
    CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows ↗
    Via MarketBeat
    News headline image
    Should You Buy Shares of CRISPR Therapeutics in February? ↗
    The company could finally be ready to deliver on years of promise. 
    Via The Motley Fool
    News headline image
    The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026 ↗
    2026 could be a big year for this company. 
    Via The Motley Fool
    News headline image
    Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss) ↗
    A sales partner offered a ray of hope that this company couldn't for itself. 
    Via The Motley Fool
    News headline image
    Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
    Opportunity knocks thrice for the iconic growth investor. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Forget AI Stocks: This Biotech Could Cure What AI Can't Touch ↗
    Artificial intelligence (AI) isn't the only industry with explosive growth potential. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Nasdaq, S&P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today ↗
    Retail sentiment on major ETFs such as SPY and QQQ remains ‘extremely bearish’ on Stocktwits. 
    Via Stocktwits
    Topics Artificial Intelligence ETFs Government
    News headline image
    Cathie Wood&#39;s Favorite Biotech Stock Is Under Pressure Amid Insider Sales And Slow Revenue Growth: Momentum Score Drops ↗
    Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ: CRSP), has come under renewed pressure in recent weeks, amid insider sales, slow revenue growth, and weak adoption of its core... 
    Via Benzinga
    News headline image
    2 Biotech Stocks That Could Soar This Year ↗
    And, if all goes well, over the next five years as well. 
    Via The Motley Fool
    News headline image
    Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
    As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    These 2 Healthcare Stocks Beat the Market in 2025. Should You Buy Them in 2026? ↗
    There are some risks to consider before jumping on the bandwagon. 
    Via The Motley Fool
    News headline image
    The $1.7 Billion Pivot: Agios Pharmaceuticals (AGIO) and the New Frontier of Oral Thalassemia Therapy
    On December 23, 2025, the biotechnology landscape shifted for thousands of patients living with chronic anemia. The U.S. Food and Drug Administration (FDA) granted approval to AQVESME (mitapivat),... 
    Via PredictStreet
    Topics Economy
    News headline image
    Is CRISPR Therapeutics Stock Yesterday's News? ↗
    The biotech sells blood disorders treatment, Casgevy. 
    Via The Motley Fool
    News headline image
    3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term ↗
    All three companies' businesses are on the verge of long-term growth explosions. 
    Via The Motley Fool
    News headline image
    Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026? ↗
    Next year could be crucial for the company as sales for its only approved treatment could take off. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    35 36 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.